Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 3Renal Insufficiency 1Recurrence 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Metatropic dwarfism 1Lymphoma, Follicular 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 7Cisplatin 6Cetuximab 4zalutumumab 3Radiotherapy 2Paclitaxel 2Nivolumab 2Gefitinib 2Fluorouracil 2sintilimab 1osimertinib 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1Taxes 1Pemetrexed 1Papanicolaou Test 1Injections, Subcutaneous 1Human Papillomavirus DNA Tests 1Gemcitabine 1Dimethyl Sulfoxide 1Colposcopy 1Cilengitide 1Ascorbic Acid 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Squamous Cell × Cilengitide × Clear all
NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡